Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus everolimus starting dose comparison in previously treated advanced renal cell carcinoma
NL-OMON50669Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib and everolimus in renal cell carcinoma (RCC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Objective response rate at Week 24 and Proportion with intolerable Grade 2 or any Grade 3 or higher treatment-emergent adverse events within 24 weeks. Started Apr 2018; status: completed.
02
Drugs
lenvatinibeverolimus
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON50669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50669.